Menu
Search
|

Menu

Close
X

Aptose Biosciences Inc APTO.OQ (NASDAQ Stock Exchange Capital Market)

2.63 USD
-- (--)
As of Feb 22
chart
Previous Close 2.63
Open --
Volume --
3m Avg Volume 75,451
Today’s High --
Today’s Low --
52 Week High 3.87
52 Week Low 0.78
Shares Outstanding (mil) 27.50
Market Capitalization (mil) 72.54
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, CAD)
FY17
0
FY16
0
FY15
0
EPS (CAD)
FY17
-0.540
FY16
-1.476
FY15
-1.224
*Note: Units in Millions of Canadian Dollars
**Note: Units in Canadian Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.75
Price to Sales (TTM)
vs sector
--
8.23
Price to Book (MRQ)
vs sector
6.74
5.26
Price to Cash Flow (TTM)
vs sector
--
26.16
Total Debt to Equity (MRQ)
vs sector
0.00
15.44
LT Debt to Equity (MRQ)
vs sector
0.00
12.05
Return on Investment (TTM)
vs sector
-139.13
13.63
Return on Equity (TTM)
vs sector
-139.13
15.25

EXECUTIVE LEADERSHIP

William Rice
Chairman of the Board, President, Chief Executive Officer, Since 2013
Salary: $321,493.00
Bonus: $141,217.00
Gregory Chow
Chief Financial Officer, Senior Vice President, Since 2014
Salary: $201,573.00
Bonus: $81,525.00
Denis Burger
Independent Director, Since 2011
Salary: --
Bonus: --
Erich Platzer
Independent Director, Since 2014
Salary: --
Bonus: --
Bradley Thompson
Independent Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

5955 Airport Rd Suite 228
MISSISSAUGA   ON   L4V 1R9

Phone: +1647.4799828
Site: aptose.com/

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

SPONSORED STORIES